| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GDC-0941 | FIMM | pan-cancer | AAC | -0.0047 | 1 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.001 | 1 |
| mRNA | ZSTK474 | CTRPv2 | pan-cancer | AAC | -0.00083 | 1 |
| mRNA | SR8278 | CTRPv2 | pan-cancer | AAC | -0.0025 | 1 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.003 | 1 |
| mRNA | UNC0321 | CTRPv2 | pan-cancer | AAC | -0.00061 | 1 |
| mRNA | Cyclopamine | FIMM | pan-cancer | AAC | -0.002 | 1 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.00032 | 1 |
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | 0.00019 | 1 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | -0.00018 | 1 |